From Australia to the world: democratising information to higher perceive IBD

Australia-based not-for-profit organisation Crohn’s Colitis Treatment (CCCure) has lately launched subscription-based entry to its registry of knowledge on sufferers coping with inflammatory bowel ailments.

The IBD-focused charity claims to have one of many world’s largest databases of real-time patient-reported and scientific information on IBD, together with Crohn’s illness, ulcerative colitis, and IBD-undetermined.


Its scientific administration system, Crohn’s Colitis Care (CCCare), options IBD-specific EMR that facilitates care documentation in close to real-time. Holding the most important structured dataset in Australia, it has roughly 300 scientific customers and 14,500 affected person data, representing over 45,000 scientific encounters and about 30,000 affected person years. Launched in 2018, the EMR is out there on the level of care and regularly refreshes with each affected person and clinician interplay. Moreover, it may be used as a guided observe instrument, in contrast to generic EMRs, CCCure claims.

The system additionally includes a client portal the place sufferers can self-report and share their well being info with scientific groups. 

Working as a stand-alone, cloud-based system that’s accessible through net browsers, CCCare can generate care plans and session letters, which could be uploaded to different scientific administration methods or emailed to clinicians anyplace. 

Affected person-reported and scientific information are additionally linked to a scientific high quality registry (CQR) the place it’s routinely de-identified/anonymised. Work is in progress to incorporate biological information within the system. 

CCCare is now utilized in over 20 IBD clinics in Australia and New Zealand with 10 extra within the strategy of onboarding. It’s also being evaluated for adoption in healthcare settings in the US, Europe, Japan, and the United Arab Emirates.

Lately, CCCure partnered with main pathology distributors to allow the reside integration of pathology outcomes into CCCare. The corporate can also be arranging the information output to the Australian authorities’s My Well being Document and direct EMR integrations with main hospitals. 


Circumstances of IBD are on the rise. In 2019, almost 5 million folks had been dwelling with the illness, leaping from three million over the previous 30 years. Throughout the identical interval, instances in Asia confirmed an growing development.

With no recognized remedy, IBD sufferers would require specialist, multidisciplinary care – and for a lifetime. Efforts have been rolling to seek out personalised, focused and efficient therapies for IBD. For CCCure CEO Invoice Petch, the important thing to that is entry to real-world IBD information and insights. 

“IBD is rising in elements of the world and demographics it has by no means been seen earlier than, so fairness of entry to confirmed therapies and the necessity for a extra private, patient-focused strategy to care is essential, in Australia, New Zealand, and globally,” he mentioned. In Australia, the illness could have an effect on as much as 300,000 folks by 2030. 

CCCare, Petch continues, can present “insights that may usually be troublesome and dear to entry.” “Moderately than preserving it locked away, we’ve opened it up so we will enhance IBD care proper now.”

Because it opens its huge database to the world, CCCure employs a variety of measures to guard affected person and scientific information, together with multi-factor authentication, role-based safety, Azure Energetic Listing integration, HTTPS entry, row-level safety, dynamic information masking, clear information encryption, and complete logging and reporting of consumer actions. It additionally has geolocated cloud storage, undergoes annual penetration testing, and segments identifiable information from websites. Furthermore, it has strict protocols to detect uncommon utilization patterns.

The corporate is at the moment in superior discussions with industrial companions and hospitals world wide for a subscription to its IBD registry. A significant pharmaceutical firm lately made the primary subscription to CCCare information for R&D. 


Initiatives have been made internationally to rework information into insights that may result in more practical methods for managing IBD. Israeli startup CytoReason, as an example, has partnered with Swiss pharma Ferring Prescribed drugs to seek out new therapies for IBD. They’re constructing cell-centred illness fashions powered by CytoReason’s AI and leveraging public and proprietary molecular information to deal with IBD on the mobile degree.

In the meantime, CCCure acknowledges the potential of its “versatile” scientific administration system to be tailored to different illness pathways sooner or later. “[W]hile our focus stays on optimising IBD care, we recognise the potential for our mannequin to increase its impression to different healthcare domains in the long run.”


“Actual-time entry to information and insights is pivotal in revolutionising IBD administration in direction of personalised and focused approaches. The traditional timeline of roughly 17 years for analysis to translate into routine care is impractical for sufferers needing optimum care at this time. CCCare’s strategy, with its steady audit output, accelerates the mixing of cutting-edge information into scientific observe, empowering healthcare suppliers to ship more practical and tailor-made care instantly. This not solely enhances the standard of care for people with IBD but in addition advances our collective journey in direction of discovering a remedy. The urgency of optimising care now and being instrumental within the pursuit of a remedy underscores the importance of real-time information accessibility in reworking IBD administration,” mentioned Jane Mary Andrews, board chair of CCCure and scientific professor on the College of Adelaide Faculty of Drugs.

HIMSS 2024 Know Earlier than You Go

How To Create An FSA ID